Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy
Author Information
Author(s): Castillo-Trivino Tamara, Mowry Ellen M., Gajofatto Alberto, Chabas Dorothee, Crabtree-Hartman Elizabeth, Cree Bruce A., Goodin Douglas S., Green Ari J., Okuda Darin T., Pelletier Daniel, Zamvil Scott S., Vittinghoff Eric, Waubant Emmanuelle
Primary Institution: University of California San Francisco
Hypothesis
The effect of natalizumab monotherapy in patients with breakthrough disease is unknown.
Conclusion
Switching to natalizumab or immunosuppressants in patients with breakthrough disease is effective in reducing clinical activity of relapsing MS.
Supporting Evidence
- Relapse rate decreased by 70% in switchers to natalizumab.
- Relapse rate decreased by 77% in switchers to immunosuppressants.
- Relapse rate in non-switchers did not decrease.
Takeaway
If people with multiple sclerosis are not doing well on their first medicine, switching to a different medicine can help them feel better.
Methodology
This is an open-label retrospective cohort study of 993 patients seen at least four times at the UCSF MS Center.
Potential Biases
Differences in the groups that led to a different response to second-line therapies may exist.
Limitations
The treatment assignment was not randomized, which may lead to differences in response to therapies.
Participant Demographics
Patients included had relapsing-remitting or relapsing secondary progressive MS.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 50,82%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website